Sutter Health Breaks Ground on $442 Million Neuroscience Complex in San Francisco
SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) — Sutter Health today broke ground on the new Sutter Advanced Neuroscience Complex at Mission Bernal – a major milestone in expanding access to high-quality neurological and neurosurgical care in Northern California. The five-story, 129,000-square-foot facility will be located at the corner of César Chávez and Valencia streets (3555 César Chavez Street) in San Francisco and is expected to open in 2028. Designed as a regional destination for brain health, the complex will unite care delivery, advanced diagnostics and research in one location.
'Sutter Health has a bold vision for brain health, and that vision includes building a state-of-the-art advanced neuroscience complex in San Francisco,' said Sutter Health President and CEO Warner Thomas. 'CPMC has cared for this community since the 1850s, and we're proud to continue that legacy by investing in a destination for neurological care that will serve patients and families locally and across the region. Our mission drives us to deliver accessible, high-quality care that fuels innovation and expands access so that more people can benefit from the highest standards of neurological health closer to home.'
'San Francisco is leading the nation in providing cutting-edge health care, and this project will bring exceptional neurological care to the heart of our city and better health outcomes for our residents,' said Mayor Daniel Lurie. 'Thank you to Sutter Health for their commitment to our city, to our residents, and to the Mission District. Together, we're building stronger, healthier communities and strengthening San Francisco's comeback.'
High-Tech Hub for Brain Health
This $442 million investment underscores Sutter Health's long-term commitment to expanding access to specialized, high-acuity care in San Francisco and the broader Bay Area. When complete, the Sutter Advanced Neuroscience Complex at Mission Bernal will bring together approximately 80 physicians and clinicians across range of neurological specialties – including Alzheimer's disease and dementia, ALS, headache, neurosurgery, neurology, epilepsy, neuro-oncology and movement disorders – to deliver seamless, integrated care in one location.
The new complex will house a full spectrum of services, including neurology, neurosurgery, imaging, lab, infusion, rehabilitation and an on-site ambulatory surgery center. Patients will also benefit from direct access to leading research and clinical trials, further supporting advancements in diagnosis and treatment.
Two of Sutter's nationally recognized programs – the Ray Dolby Brain Health Center and the Forbes Norris MDA/ALS Research and Treatment Center – will relocate to the new complex, enabling greater capacity and deeper collaboration among specialists.
The site will also include underground parking to improve convenience for patients and visitors. In a related investment, Sutter plans to add two neurological intervention suites to the adjacent CPMC Mission Bernal campus hospital by 2027. These suites will offer advanced imaging and enable rapid detection and minimally invasive treatment of life-threatening neurological conditions.
'Our goal is to provide coordinated, comprehensive access to integrated care that merges the expertise of neurologists and neurosurgeons,' said Dr. Lewis Leng, a neurosurgeon with Sutter West Bay Medical Group. 'The new Sutter Advanced Neuroscience Complex at Mission Bernal will create more access to care for patients with neurological conditions and provide them the opportunity to take advantage of Sutter's award-winning neuroscience treatment and clinical research.'
Christina Oh, president of Sutter's Greater San Francisco Division, added, 'Patients will be able to come to this location and visit their specialist, receive diagnostic lab and imaging, as well as outpatient procedures all in one complex. Having all these services under one roof will create a more convenient, coordinated experience.'
The Sutter Advanced Neuroscience Complex is part of Sutter Health's broader strategy to invest nearly $1 billion in healthcare infrastructure across San Francisco over the next five years. This initiative aims to significantly expand access to specialized medical care, such as Sutter's new Otolaryngology-Head and Neck Surgery program, and enhance the overall patient experience.
A Vision for Advanced Care and Clinical Training
The Mission Bernal Care Complex is part of a larger effort by Sutter Health to address the growing healthcare needs of Northern California, with more than two dozen new facilities currently in development. Beyond expanding access, this complex reflects Sutter's strong commitment to education and workforce development, with plans to train over 1,000 medical residents and fellows by 2030. Sutter CPMC plays a key role in this effort, currently training residents and fellows in nationally accredited Graduate Medical Education programs across a wide range of specialties, including advanced heart failure and transplant cardiology, cardiovascular disease, internal medicine, gastroenterology, hand surgery, hematology-oncology, ophthalmology, pulmonary and critical care medicine, psychiatry and transplant hepatology. CPMC also offers additional training in neurocritical care, among other areas.
'This groundbreaking represents a pivotal moment in advancing Sutter Health's mission to provide high-quality, compassionate and innovative care,' said Ken McNeely, chair of the Sutter Health Board of Directors. 'It reflects our dedication to meeting the evolving healthcare needs of our community while preparing the next generation of physicians and care teams to carry that mission forward.'
For more information about the Sutter Advanced Neuroscience Complex at Mission Bernal and Sutter Health's ongoing commitment to healthcare excellence, please visit www.sutterhealth.org.
About Sutter Health
Sutter Health is a not-for-profit health care system dedicated to providing comprehensive care throughout California. Committed to community partnerships and innovative, high-quality patient care, Sutter Health is pursuing a bold new plan to reach more people and make excellent health care more connected and accessible. Sutter Health currently serves nearly 3.5 million patients, thanks to a dedicated team of more than 57,000 employees and clinicians and 12,000+ affiliated physicians, with a unified focus on expanding care to serve more patients.
Sutter delivers exceptional and affordable care through its hospitals, medical groups, ambulatory surgery centers, urgent care clinics, telehealth, home health, and hospice services. Dedicated to transforming health care, at Sutter Health, getting better never stops.
Learn more about how Sutter Health is transforming health care at sutterhealth.org and vitals.sutterhealth.org.
Attachments Artist rendering: Sutter Advanced Neuroscience Complex in San Francisco
Groundbreaking for Sutter Advanced Neuroscience Complex in San Francisco
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate (PPi) efflux via on-target engagement of the ABCC6 membrane transporter and reduced vascular calcification in animal models of CKD BOSTON, June 06, 2025 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., ('Rectify') a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane protein function, today showcased new data from its cardiorenal program with its ABCC6-targeting PFM, RTY-822. The results were presented in an oral presentation during the European Renal Association (ERA) 2025 Congress, taking place in Vienna, Austria, June 4 – 7, 2025. 'These translational results demonstrate that Rectify's PFM reduces vascular calcification and kidney injury and improves kidney function through enhancement of ABCC6 function,' said Rajesh Devraj, Ph.D., President and Chief Executive Officer of Rectify. 'We believe the strength of these data underscores the potential of our approach to offer a novel and differentiated therapeutic strategy to treat renal dysfunction and injury, as well as address vascular calcification driving cardiovascular disease. We are committed to continuing to advance meaningful therapies for patients with CKD and serious cardiovascular conditions.' Robert Hughes, Ph.D., Chief Scientific Officer of Rectify, added, 'Enhancing the function of ABCC6 holds the potential to address key drivers of vascular calcification and tubular dysfunction seen in CKD. With demonstrated on-target engagement, RTY-822 shows significant promise to reduce CKD-associated calcium deposits in arterial walls, a well-established contributor to cardiovascular morbidity and mortality seen in patients with CKD, and remarkably, also improves glomerular function and tubular injury. The translational readiness of this program makes it a compelling de-risked asset with the potential to address CKD and multiple cardiovascular indications.' Title: A Positive Functional Modulator of ABCC6 Decreases Vascular Calcification and Improves Kidney Function in a Rat Adenine Diet Model of Chronic Kidney DiseaseAbstract Number: 1723 Presenter: John Miller, Ph.D. Session: Chronic Kidney Disease, Focused Oral Room 4Date and Time: Friday, June 6, 2025, 8:51 a.m. – 8:57 a.m. CEST In CKD, reduced ABCC6 activity or expression may lead to lower PPi levels, contributing to pathological calcification in blood vessels and kidneys. Restoring ABCC6 function or enhancing its expression offers a new and compelling therapeutic strategy to prevent the progression of CKD towards end-stage renal disease in addition to reducing large vessel calcification, a major driver of cardiovascular complications in CKD. Key findings RTY-822, an orally administered PFM targeting ABCC6 increased both ABCC6 protein expression and plasma PPi levels in primary human hepatocytes, supporting its proposed mechanism of action In a rat model of CKD and vascular calcification induced by an adenine-enriched diet with calcitriol supplementation: RTY-822 treatment led to statistically significant reductions in vascular calcification in the aorta and the femoral arteries After a six-week treatment course, RTY-822 improved glomerular and tubular kidney functions, with statistically significant reductions in serum creatinine, urea, and cystatin C, and an improved estimated glomerular filtration rate (eGFR) Calcium accumulation in the kidney was also significantly reduced Kidney injury biomarkers were reduced, including a significant decrease in plasma KIM-1 and urinary Lipocalin-2 (NGAL) levels In rats fed an adenine-rich diet without calcitriol supplementation, treatment with RTY-822 resulted in: Improved glomerular and tubular kidney functions Reduced serum creatinine and cystatin C levels Increased eGFR Reduced urinary NGAL levels, a biomarker of acute kidney injury The presentation is available on the Rectify website at About Rectify Pharmaceuticals, Inc. ('Rectify') Rectify is advancing Positive Functional Modulators (PFMs), a novel class of oral, small molecules that restore and enhance membrane protein function to address the underlying cause of serious diseases. Rectify's PFMs have potential to modulate the activity of wild-type and mutated membrane-bound proteins, a historically difficult challenge with a small molecule approach. The Company's breakthrough product platform enables efficient and rapid discovery of first- and best-in-class small molecule therapies with the potential to address membrane protein dysfunction for treatment of rare and common diseases, including liver, cardio-renal-metabolic, and neurodegenerative diseases. Rectify was founded and seeded by Atlas Venture who co-led the $100M Series A round with Omega Funds and were joined by Forbion and Longwood Fund. For more information, please visit or follow us on X and LinkedIn. ContactMediaJonathan PappasLifeSci Communicationsjpappas@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment
Discover the future of the Molecular Diagnostics - Infectious Disease sector with our comprehensive report. Explore how multiplex assays and rapid testing are transforming diagnosis and treatment amidst the boom in biotechnology and genomics. This detailed analysis covers dynamic trends such as pathogen evolution, globalization, and climate change impacts. Benefit from extensive insights, including U.S. Medicare Fee Schedules, and detailed global data. Equip your organization with expert knowledge today. Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets 2025-2029: Strategies, Trends, and Forecasts by Application, Place and Country with Market Analysis & Executive Guides" report has been added to offering. The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for further growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what's happening in this informative report - and find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever. The report has hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing along with the most frequently used and billed tests. The report includes detailed breakouts for 15 countries and 4 regions. A detailed breakout for any country in the world is available to purchasers of the report. This research makes you the expert in your organization. Assistance and additional specific data is provided without additional charges. All report data is available in Excel format on request. Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication. Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this report. A range of dynamic trends are pushing market growth and company valuations. Trends like: Multiplex testing Pathogen evolution and pandemics Biotechnology advances in genetics Climate change Globalization The rise of rapid testing Key Topics Covered: 1 Market Guides1.1 Situation Analysis2 Introduction and Market Definition2.1 Market Definition2.1.1 Market Size2.1.2 Currency2.1.3 Years2.2 Methodology2.2.1 Methodology2.2.2 Sources2.2.3 Authors2.3 Perspective: Healthcare Spending2.3.1 Global Healthcare Spending2.3.2 Spending on Healthcare and Pharmaceuticals2.3.3 Spending on Diagnostics2.3.4 Important Role of Insurance for Medical Services2.4 The Nature of the IVD Product2.4.1 Features Overview2.4.2 The Misunderstood Feature2.4.3 Regulation2.4.4 The Newest Feature2.4.5 The Oldest Feature2.4.6 All About Scope2.4.7 Why Turnaround is Becoming More Important2.4.8 The Role of Trust2.5 The IVD Product of the Future3 Infectious Diseases - Guide to the Pathogens3.1 Infectious Disease Pathogens - The Big Picture3.1.1 Viruses3.1.2 Bacteria3.1.3 Fungi3.1.4 Parasites3.1.5 Prions3.1.6 Virulence3.1.7 Transmission3.2 The Coronavirus3.2.1 Severe acute respiratory syndrome (SARS)3.2.2 Middle East respiratory syndrome (MERS)3.2.3 COVID-19. The SARS CoV 2 Virus3.2.3.1 Signs and symptoms3.2.3.2 Transmission3.2.3.3 Diagnosis3.2.3.4 Prevention3.2.3.5 Management3.2.3.6 Prognosis4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body4.2 The Clinical Laboratory Market Segments4.2.1 Traditional Market Segmentation4.2.2 Laboratory Focus and Segmentation4.2.3 Segmenting the Syndromic Testing Market4.3 Industry Structure4.3.1 Hospital Testing Share4.3.2 Economies of Scale4.3.3 Hospital vs. Central Lab4.3.4 Physician Office Lab's4.3.5 Physician's and POCT5 Market Trends5.1 Factors Driving Growth5.1.1 The Nucleic Acid Impact5.1.2 Population Dynamics5.1.3 The Developing World5.1.4 Decentralization5.1.5 Self Testing5.1.6 The Need for Speed5.2 Factors Limiting Growth5.2.1 Costs and Experience Curve Effects5.2.2 The Role of ID Prevalence5.2.3 Wellness5.2.4 The Impact of Living Standards5.3 Instrumentation, Automation and Diagnostic Trends5.3.1 Traditional Automation and Centralization5.3.2 The New Automation, Decentralization and Point of Care5.3.3 Instruments Key to Market Share5.3.4 Bioinformatics Plays a Role5.3.5 PCR Takes Command5.3.6 Next Generation Sequencing Fuels a Revolution5.3.7 NGS Impact on Pricing5.3.8 Whole Genome Sequencing, A Brave New World5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment6 Clinical Laboratory MDx Infectious Disease Recent Developments6.1 Recent Developments - Importance and How to Use This Section6.1.1 Importance of These Developments6.1.2 How to Use This Section6.2 Presymptom Health Nabs Funding for Sepsis Test6.3 FDA Clears BioMerieux GI Panel6.4 Rapid Infection Diagnostic Launches BSIDx6.5 Biotia's AI-, Sequencing-Based UTI Test approved6.6 Delve Bio, Broad Clinical Labs Partner for Metagenomic6.7 Roche Respiratory Panel Receives FDA EUA6.8 Genetic Signatures Gets Approval for GI Parasite Panel6.9 Diasorin Expands Respiratory Panel6.10 BioMerieux Outlines MDx-Driven Growth6.11 T2 Biosystems Gets Extended T2Bacteria Panel6.12 Diasorin Aims to Deliver Updated Instruments, New Assays6.13 Oxford Nanopore Nabs Investment From BioMerieux6.14 Day Zero Diagnostics Closes Financing Round6.15 Spindiag Seeks Investors for Rapid PCR System6.16 Sorrento Therapeutics Nabs Contract for Dx Platform6.17 Kephera Planning Menu of Infectious Disease Tests6.18 Oxford Nanopore and BioMerieux to Develop IDDx6.19 SD Biosensor Eyes Global Expansion6.20 Selux Dx Next Gen Phenotyping Gets FDA Clearance6.21 Takara Developing High-Throughput Multiplex Panels6.22 BioGX Debuts New Point-of-Care Molecular Testing System6.23 Nanopath MDx Platform Providing 15-Minute Results6.24 ProtonDx Commercializing Rapid MDx Instrument6.25 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays6.26 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS6.27 Accelerate Diagnostics Anticipates Growth6.28 Lumos Diagnostics Expanding Test Portfolio6.29 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens7 Key Companies7.1 Abbott Laboratories7.2 Agilent7.3 Altona Diagnostics7.4 Anitoa7.5 Autonomous Medical Devices7.6 Beckman Coulter Diagnostics (Danaher)7.7 Becton, Dickinson and Company7.8 BioGX7.9 Biomatik7.10 bioMerieux Diagnostics7.11 Bio-Rad Laboratories, Inc.7.12 Cepheid (Danaher)7.13 Diasorin S.p.A.7.14 DNAe7.15 Flow Health7.16 Global Access Diagnostics7.17 Great Basin Scientific, Inc.7.18 Hologic7.19 Novacyt7.20 Novus Diagnostics7.21 Oncimmune7.22 One Codex7.23 OraSure Technologies7.24 Prometheus Laboratories7.25 Qiagen7.26 QuidelOrtho7.27 R-Biopharm AG7.28 Response Biomedical7.29 Revvity7.30 Roche Diagnostics7.31 Siemens Healthineers7.32 Thermo Fisher Scientific7.33 Vela Diagnostics7.34 Veredus Laboratories7.35 YD Diagnostics7.36 Zhejiang Orient Gene Biotech8 The Global Market for Clinical Laboratory MDx Infectious Disease8.1 Global Market Overview by Country8.2 Global Market by Application - Overview8.3 Global Market by Place - Overview9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application9.1 Respiratory9.2 Blood Borne Virus9.3 Transplant9.4 Hospital Acquired Infections9.5 Reproductive Health9.6 C19 Singleplex9.7 Meningitis9.8 Gastrointestinal9.9 Tropical10 Global Clinical Laboratory MDx Infectious Disease Markets - By Place10.1 Hospital Lab10.2 Outpatient Lab10.3 Point of Care10.4 Other Place11 Appendices11.1 Growth of Approved IVD Test Menu11.2 Growth of Approved Average IVD Test Fee11.3 The Most Used IVD Assays11.4 The Highest Grossing Assays11.5 Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
2 hours ago
- Yahoo
2025 Aromatherapy and Essential Oils Market Analysis Report: Holistic-Well-Being, Transparency, Sustainable Practices, Certifications and Claims, and AI-Powered Personalized Scents
The Global Aromatherapy and Essential Oils Market is poised for substantial growth, with a forecasted CAGR over 6%, driven by heightened well-being awareness and social media influence. Valued at over $8 billion in 2024, North America leads with 45% market share, fueled by holistic wellness trends. Asia-Pacific follows closely, propelled by demographic changes and Gen Z's health focus. Companies prioritizing personalized, natural solutions will thrive. The comprehensive report includes market size, revenue forecasts, trends, and more. Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "2025 Aromatherapy and Essential Oils Market" report has been added to offering. The Global Aromatherapy and Essential Oils Market is set for consistent growth, with a projected CAGR exceeding 6% during 2024-2031 This expansion is driven by a growing emphasis on well-being, the rise of the she economy, the influence of social media, direct selling model and the increasing adoption of complementary and alternative medicine. The global market was valued over $8 billion in 2024. North America made up the largest portion of the global market with over 45% in revenues in 2024, followed by Asia Pacific with over 40% of revenues. The North American market is being driven by growing consumer interest in holistic wellness and natural remedies. As people become more focused on mental and emotional health, essential oils are being used for anxiety relief, stress management, and mindfulness. The rising awareness of sleep hygiene has also fueled demand for essential oil blends that promote relaxation and better sleep. Wellness brands are responding by offering more specialized products. The Asia-Pacific region is witnessing significant demographic and lifestyle shifts that are reshaping the wellness industry. Two primary factors driving this transformation are the aging population and the growing health-consciousness of younger generations like Gen Z. These changes are boosting the demand for products and services focusing on overall well-being. As European consumers continue to prioritize personalized and natural wellness solutions, the aromatherapy and essential oils market is poised for sustained growth. Companies that align their product lines with specific consumer needs, while emphasizing safety, sustainability, and quality, will remain competitive in this evolving landscape. Report Scope A comprehensive analysis of the Global Aromatherapy and Essential Oils Market for North America, Latin America, Europe, Asia-Pacific, and Rest of World, which includes market sizing, market share by competitor, drivers, restraints, regional trends and revenue forecasts to 2031. Essential oils are defined as natural oils, typically obtained by distillation, having the characteristic fragrance from the plant or other source extraction. Technically, aromatherapy means the use of aromas as therapy or the use of aromas for their healing properties. However, there is an increasing move to use the term 'essential oils' (which more accurately describes the existing market) as the therapeutic use of essential oils based on their aroma and properties, which includes internal use of the oils. For purposes of this research, only essential oils that are used for health and wellness and relaxation purposes via topical application, inhalation, diffusion, and ingestion have been included. The report includes the following information: Market Size, Growth Rate, Revenue Forecast (2024-2031) Revenue Share by Segment (distribution channel, product type, customer segment) Growth Drivers & Restraints Competitive Factors Industry Challenges Market Trends Regional Trends Pricing Trends Distribution Trends Regulatory Information Major Company Profiles Every report purchase comes with 1 hour of Analyst Inquiry Time for a phone call with the analysts. This can be used for strategic advice, consultation, or addressing issues in your business and linking them to a solution. Analyst Inquiry Time must be used within 45 days of report purchase. Key Topics Covered: 1. Research Scope, Methodology, Definition 2. Executive Summary Major Data Points - Global Revenue by Region, 2024 Revenue, Global, 2019-2024 3. Competitive Factors 4. Consumer Behavior 5. Market Drivers and Impact 6. Market Restraints and Impact 7. Global Trends Holistic-Well-Being Transparency Sustainable Practices Certifications and Claims AI-Powered Personalized Scents 8. Market Data - Global Total Market Revenue and Forecast Market Share by Company Distribution Share Analysis Market Share by Product Type 9. Competitive Landscape dOTERRA International, LLC Young Living Essential Oils, LC Melaleuca, Inc. 10. North America Major Data Points Consumer Behavior Market Drivers and Impact Market Restraints and Impact Market Trends Market Data 11. Asia-Pacific Major Data Points Consumer Behavior Market Drivers and Impact Market Restraints and Impact Market Trends Major Markets - China, South Korea, Japan, and Australia Market Data 12. Europe Major Data Points Consumer Behavior Market Drivers and Impact Market Restraints and Impact Market Trends Major Markets - Germany, and United Kingdom Market Data 13. Latin America Major Data Point Consumer Behavior Market Drivers and Impact Market Restrains and Impact Market Trends Market Data 14. Market Data - Rest of the World Companies Featured doTERRA Young Living Melaleuca Inc. Ryohin Keikaku Co. Ltd. Plant Therapy Neal's Yard Remedies Jurlique Saje Natural Business Inc. Frontier Co-op (Aura Cacia) Rocky Mountain Oils Eden Botanicals Melaleuca Plant Therapy rareEssence Eden Gardens Essential oils Nature Packaged Swiss Just America Exotic Aroma Perfect Potion Essentials Quintis @aroma Primavera Life GmbH First Natural Brands (Tisserand) Farfalla Terra Gaia Florihana Neom well-being Aromatherapy Associates Absolute Aromas For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
